Industry News
Pharmaceutical Industry News
Less than two weeks after Pfizer…
Less than two weeks after Pfizer struck a deal with Sciwind Biosciences to gain commercial rights to a GLP-1 drug, China's National Medical Products Administration (NMPA) has approved the treatment for patients with obesity.
Servier on Friday unveiled a deal…
Servier on Friday unveiled a deal to acquire Day One Biopharmaceuticals—a commercial-stage company developing targeted therapies for pediatric cancers and other diseases—for $21.50 per share in cash. The total value of the deal, which is
Kyowa Kirin has decided to…
Kyowa Kirin has decided to discontinue all clinical development of its OX40 drug after two new cancer cases emerged. Sanofi is committing up to $1.5 billion for global rights to Sino Biopharm's first-in-class JAK/ROCK inhibitor.
La mayoría de los pacientes mantendrían su peso con menos dosis de medicamentos GLP-1
En una investigación reciente, un pequeño grupo de pacientes recibió las inyecciones con menos frecuencia, pero aun así mantuvo la pérdida de peso y los beneficios para la salud.
Fewer Pregnant Women Received Acetaminophen in E.R.s After White House Warnings
A new analysis of prescription data found that emergency room orders for acetaminophen for pregnant women fell for weeks after the federal warning.
F.D.A. Faces Upset Over Denials of New Drugs
Agency officials promise fast reviews of new treatments while vowing they will not be a “rubber stamp” for the industry. But patients with rare diseases view recent decisions as signs that the doors are closing
As AI and automation reshape drug…
As AI and automation reshape drug discovery, laboratories themselves are being forced to evolve. Gensler’s Ryley Poblete joins the podcast to explain how new technologies, the makeup of scientific teams and new ways of collaboration
The FDA has approved the first…
The FDA has approved the first true generic version of GSK's asthma inhaler Flovent, signing off on Glenmark's fluticasone propionate inhalation aerosol. For more than two years, Prasco Laboratories has sold an "authorized generic" version
After delivering solid sales…
After delivering solid sales growth in a difficult 2025, Germany’s Merck KGaA may have a tougher go of things this year, which the company is crediting in part to a predicted onslaught of U.S. generics
Galderma has doubled its peak…
Galderma has doubled its peak annual sales estimate for Nemluvio (nemolizumab) to more than $4 billion, following what CEO Flemming Ørnskov described as an “outstanding launch trajectory” for the Dupixent competitor in its first full
Leo Pharma has decided “It’s…
Leo Pharma has decided “It’s GO time” for the launch of its JAK inhibitor cream Anzupgo. Having built its growth plans on the recently approved medicine, the Danish drugmaker is running a direct-to-consumer campaign, including
Forma Life Sciences, which…
Forma Life Sciences, which inherited BioDuro’s California operations earlier this year, officially launched as a CDMO with a focus on oral solid dosage drugs this week.
Most Patients Keep Weight Off With Fewer GLP-1 Shots, Study Finds
In a recent review, a small group of patients received the injections less frequently but still maintained weight loss and health benefits.
Eli Lilly has officially launched…
Eli Lilly has officially launched Employer Connect, its direct-to-employer platform for its obesity medications, after teasing the rollout late last year.
Collegium Pharmaceutical has…
Collegium Pharmaceutical has tapped an appropriately glitzy star as the face of a new campaign spotlighting the bright side of life with attention-deficit/hyperactivity disorder.
BioDuro, headquartered in…
BioDuro, headquartered in California, has set up a new joint venture with Taiwan drug ingredients manufacturer, Cenra API Solutions. The new enterprise will see Cenra’s commercial-scale facility in Taipei folded into BioDuro’s production network.
The company has been pressing the…
The company has been pressing the FDA to hold a formal hearing on its proposed jet lag label expansion for Hetlioz since it was first snubbed way back in 2019.
The primary growth drivers in…
The primary growth drivers in Bayer’s pharma sector—Nubeqa and Kerendia—are performing even better than the company anticipated and their momentum is expected to continue in 2026. But that won’t lead to growth of Bayer’s pharma
Not long after Novo Nordisk…
Not long after Novo Nordisk received an untitled letter from the FDA disputing certain elements of the first TV spot for its Wegovy pill, another of the Danish drugmaker’s GLP-1 ads is in the regulator’s
Traditional feasibility misses…
Traditional feasibility misses critical signals about patient reality. Patient journey intelligence reveals them, making truly patient-centric trials possible.